Eszopiclone

Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a cyclopyrrones.

Its main selling point is that it is approved by the U.S. Food and Drug Administration for long-term use, unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia.

Pharmacodynamics

Eszopiclone is a hypnotic with a chemical structure unrelated to anxiolytic properties. [1]

Pharmacokinetics

The half-life (t½) of approximately 6 hours. In healthy adults, Lunesta does not accumulate with once-daily administration, and its exposure is dose-proportional over the range of 1 to 6 mg. In patients 65 years of age and older, there is a slight prolonged elimination of eszopiclone (t½ of approximately 9 hours). Therefore, in elderly patients the starting dose of Lunesta should be decreased to 1 mg and the dose should not exceed 2 mg.

Absorption

Eszopiclone is rapidly absorbed following oral administration. Peak plasma concentrations are achieved within approximately 1 hour after oral administration. Eszopiclone is weakly bound to plasma protein (52-59%). The large free fraction suggests that eszopiclone disposition should not be affected by drug-drug interactions caused by protein binding. The blood-to-plasma ratio for eszopiclone is less than one, indicating no selective uptake by red blood cells.

Metabolism

Following oral administration, eszopiclone is extensively metabolized by CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.

After oral administration, eszopiclone is eliminated with a mean t½ of approximately 6 hours. Up to 75% of an oral dose of racemic zopiclone is excreted in the urine, primarily as metabolites. A similar excretion profile would be expected for eszopiclone, the S-isomer of racemic zopiclone. Less than 10% of the orally administered eszopiclone dose is excreted in the urine as parent drug.

In healthy adults, administration of a 3 mg dose of eszopiclone after a high-fat meal resulted in no change in AUC, a reduction in mean Cmax of 21%, and delayed T-max by approximately 1 hour. The half-life remained unchanged, approximately 6 hours. The effects of Lunesta on sleep onset may be reduced if it is taken with or immediately after a high-fat/heavy meal. Sepracor, the drug's manufacturer and developer, recommends against using eszopiclone immediately following a meal due to this interference.

Eszopiclone may take up to 7 to 10 days before sleep quality significantly improves.

Side Effects

Common side effects can include:

• unpleasant bitter or metallic taste/smell
• headaches
• cold-like symptoms
• pain
• daytime drowsiness
• lightheadedness
• dizziness
• loss of coordination
• upset stomach
• vomiting
• decreased sexual desire
• painful menstruation (periods)
• breast enlargement in males
• heartburn
• unusual dreams

Less common side effects can include:

• rashes
• itching
• chest pain
• swelling of the hands, feet, ankles, or lower legs
• painful or frequent urination
• bloody or cloudy urine
• back pain

If a person does not sleep immediately after taking their Eszopiclone (Lunesta) or if they get up shortly after taking their medication they may experience dizziness, lightheadedness, hallucinations (seeing things or hearing voices that are not there), as well as experience problems with coordination and memory.

Withdrawal Symptoms

If a person has taken Eszopiclone for longer than 1 - 2 weeks they should not stop taking the medication abruptly and should consult their doctor. Usually doctors will direct a slow reduction in dosage to minimise withdrawal symptoms. Particularly after abrupt cessation of medication, withdrawal symptoms may include:

• anxiety
• unusual dreams
• dizziness
• stomach and muscle cramps
• upset stomach
• vomiting
• sweating
• shakiness
• insomnia
• seizures (rare)
• death by overdose (rare)

See also

• Zopiclone